Chronic neutrophilic leukemia with JAK2 gene mutation

Community Oncology

Volumn 9, Issue 4, 2012, Pages 127-131

  Ortiz Cruz, Karen ^a   Amog Jones, Glenda ^b   Salvatore, Joseph R ^b,c  

^a BANNER GOOD SAMARITAN MEDICAL CENTER   (United States)

^b CARL T HAYDEN VA MEDICAL CENTER   (United States)

^c UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; HYDROXYUREA;

ADULT; ANEMIA; ANOREXIA; BLOOD CELL COUNT; BLOOD SMEAR; BLOOD TRANSFUSION; BONE MARROW BIOPSY; CANCER GROWTH; CASE REPORT; CELL MATURATION; CHRONIC NEUTROPHILIC LEUKEMIA; COMPUTER ASSISTED TOMOGRAPHY; CONSCIOUSNESS LEVEL; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FLOW CYTOMETRY; GENE MUTATION; HEPATOSPLENOMEGALY; HOSPITAL READMISSION; HUMAN; HYPERPLASIA; JAK2 GENE; LETTER; LEUKAPHERESIS; LEUKOCYTE COUNT; LEUKOCYTOSIS; MALE; MEDICAL HISTORY; MYELOID HYPERPLASIA; NEUTROPHIL; PHYSICAL EXAMINATION; RETINA HEMORRHAGE; SURVIVAL TIME; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT DURATION;

EID: 84861541017     PISSN: 15485315     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cmonc.2012.03.012     Document Type: Letter

References (27)

1. Böhm J, Kock S, Schaefer HE, Fisch P. Evidence of clonality in chronic neutrophilic leukemia. J Clin Pathol. 2003;56(4):292-295.
2. Jaffe ES, Harris NL, Stein H, Vardiman JW. (eds). World Health Organization of Tumours: Pathology and Genetics of Tumours and Lymphoid Tissue. Lyon, France: IARC Press, 2001.
3. Tefferi A, Elliott MA, Pardanani A. Atypical myeloproliferative disorders: diagnosis and management. Mayo Clin Proc. 2006;81(4):553-563.
4. Tuohy EA. A case of splenomegaly with polymorphonuclear neutrophil hyperleukocytosis. Am J Med Sci. 1920;160:18-25.
5. Elliott MA. Chronic neutrophilic leukemia and chronic myelomonocytic leukemia: WHO defined. Best Practice and Research Clinical Hematology. 2006;19(3):571-593.
6. Goto H, Hara T, Tsurumi H, Tanabashi S, Moriwaki H. Chronic neutrophilic leukemia with congenital Robertsonian translocation successfully treated with allogeneic bone marrow transplantation in a young man. Int Med. 2009;48:563-567.
7. Piliotis E, Kutas G, Lipton JH. Allogeneic bone marrow transplantation in the management of chronic neutrophilic leukemia. Leuk Lymphoma. 2002;43:2051-2054.
8. Choi IK, Kim BS, Lee KA, et al. Efficacy of imatinib mesylate (STI571) in chronic neutrophilic leukemia with t (15;19): case report. Am J Hematol. 2004;77(4):366-369.
9. Meyer S, Feremans W, Cantiniaux B, et al. Successful alpha-2binterferon therapy for chronic neutrophilic leukemia. Am J Hematol. 1993;43(4):307-309.
10. Jones AV, Kreil S, Zoi K, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood. 2005;106(6):2162-2168.
11. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100(7):2292-2302.
12. Pane F, Frigeri F, Sindona M, et al. Neutrophilic-chronic myeloid leukemia: A distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction). Blood. 1996;88(7):2410-2414.
13. Böhm J, Schaefer HE. Chronic Neutrophilic Leukemia: 14 new cases of an uncommon myeloproliferative disease. J Clin Path. 2002;55(11):862-864.
14. Elliot MA, Hanson CA, Dewald GW, Smoley SA, Lasho TL, Tefferi A. WHO-defined chronic neutrophilic leukemia: a long term analysis of 12 cases and a critical review of the literature. Leukemia. 2005;19(2):313-317.
15. Kako S, Kanda Y, Sato T, et al. Early relapse of JAK2 V617Fpositive chronic neutrophilic leukemia with central nervous system infiltration after unrelated bone marrow transplantation. Am J Hematol. 2007;82(5):386-390.
16. Lea NC, Lim Z. Westwood NB, et al. Presence of JAK2 V617F tyrosine kinase mutation as a myeloid-linage-specific mutation in chronic neutrophilic leukemia. Leukemia. 2006;20(7):1324-1326.
17. McLornan DP, Percy MJ, Jones AV, Cross NC, McMullin MF. Chronic neutrophilic leukemia with an associated V617F JAK2 tyrosine kinase mutation. Haematologica. 2005;90(12):1696-1697.
18. Steensma DP, Dewald GW, Lasho TL, Powell HL, McClure RF, Levine RL et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorder and the myelodysplastic syndrome. Blood. 2005;106(4):1207-1209.
19. Sugino K, Gocho K, Ota H, et al. Miliary tuberculosis associated with chronic neutrophilic leukemia. Int Med. 2009;48(15):1283-1287.
20. Noguchi T, Ikeda K, Yamamoto K, et al. Severe bleeding tendency caused by leukemic infiltration and destruction of vascular walls in chronic neutrophilic leukemia. Int J Hematol. 2001;74(4): 437-441.
21. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutat6ion of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365(9464):1054-1061.
22. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7(4): 387-397.
23. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythemia vera. Nature. 2005;434(7037):1144-1148.
24. Kralovics R, Passamonti F, Buser AS, et al. A gain of function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005; 352(17):1779-1790.
25. Cankovic M, Whiteley L, Hawley RC, et al. Clinical performance of JAK2 V617F mutation detection assays in a molecular diagnostics laboratory: Evaluation of screening and quantitation methods. Am J Clin Pathol. 2009;132(5):713-721.
26. Rawlings JS, Rosler KM, Harrison DA. The JAK/STAT signaling pathway. J Cell Sci. 2004;117:1281-1283.
27. Tefferi A, Skoda R, and Vardiman JW. Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics. Nat Rev Clin Oncol. 2009;6(11):627-637.